Lannett Company - News Releases http://lannett.investorroom.com/ Lannett Announces Fiscal 2018 Fourth-Quarter And Full-Year Financial Results; Provides Guidance For Fiscal 2019 http://lannett.investorroom.com/2018-08-28-Lannett-Announces-Fiscal-2018-Fourth-Quarter-And-Full-Year-Financial-Results-Provides-Guidance-For-Fiscal-2019 Tue, 28 Aug 2018 16:15:00 -0400 http://lannett.investorroom.com/2018-08-28-Lannett-Announces-Fiscal-2018-Fourth-Quarter-And-Full-Year-Financial-Results-Provides-Guidance-For-Fiscal-2019 Lannett To Report Fiscal 2018 Fourth-Quarter And Full-Year Financial Results, Host Conference Call On Tuesday, August 28 http://lannett.investorroom.com/2018-08-22-Lannett-To-Report-Fiscal-2018-Fourth-Quarter-And-Full-Year-Financial-Results-Host-Conference-Call-On-Tuesday-August-28 Wed, 22 Aug 2018 06:52:00 -0400 http://lannett.investorroom.com/2018-08-22-Lannett-To-Report-Fiscal-2018-Fourth-Quarter-And-Full-Year-Financial-Results-Host-Conference-Call-On-Tuesday-August-28 Lannett Provides Update On Contract Renewal With Jerome Stevens Pharmaceuticals http://lannett.investorroom.com/2018-08-20-Lannett-Provides-Update-On-Contract-Renewal-With-Jerome-Stevens-Pharmaceuticals --Company Announces Preliminary Fiscal 2018 Fourth-Quarter and Full-Year Financial Results; To Host Conference Call Today at 8 a.m. ET-- Mon, 20 Aug 2018 06:53:00 -0400 http://lannett.investorroom.com/2018-08-20-Lannett-Provides-Update-On-Contract-Renewal-With-Jerome-Stevens-Pharmaceuticals Lannett Enters Licensing Agreement For Generic Concerta®, Methylphenidate Hydrochloride ER Tablets http://lannett.investorroom.com/2018-08-03-Lannett-Enters-Licensing-Agreement-For-Generic-Concerta-R-Methylphenidate-Hydrochloride-ER-Tablets Fri, 03 Aug 2018 06:52:00 -0400 http://lannett.investorroom.com/2018-08-03-Lannett-Enters-Licensing-Agreement-For-Generic-Concerta-R-Methylphenidate-Hydrochloride-ER-Tablets Lannett Announces Multiple Product Launches http://lannett.investorroom.com/2018-07-23-Lannett-Announces-Multiple-Product-Launches Mon, 23 Jul 2018 06:53:00 -0400 http://lannett.investorroom.com/2018-07-23-Lannett-Announces-Multiple-Product-Launches Lannett Announces Restructuring Plan Of Cody Laboratories Subsidiary http://lannett.investorroom.com/2018-06-29-Lannett-Announces-Restructuring-Plan-Of-Cody-Laboratories-Subsidiary Fri, 29 Jun 2018 06:52:00 -0400 http://lannett.investorroom.com/2018-06-29-Lannett-Announces-Restructuring-Plan-Of-Cody-Laboratories-Subsidiary Lannett Receives FDA Approval For Levofloxacin Oral Solution; Imminent Launch Anticipated http://lannett.investorroom.com/2018-06-01-Lannett-Receives-FDA-Approval-For-Levofloxacin-Oral-Solution-Imminent-Launch-Anticipated Fri, 01 Jun 2018 06:52:00 -0400 http://lannett.investorroom.com/2018-06-01-Lannett-Receives-FDA-Approval-For-Levofloxacin-Oral-Solution-Imminent-Launch-Anticipated Lannett Receives FDA Approval For Dronabinol Capsules http://lannett.investorroom.com/2018-05-21-Lannett-Receives-FDA-Approval-For-Dronabinol-Capsules Mon, 21 May 2018 06:53:00 -0400 http://lannett.investorroom.com/2018-05-21-Lannett-Receives-FDA-Approval-For-Dronabinol-Capsules Lannett Announces Fiscal 2018 Third-Quarter Financial Results http://lannett.investorroom.com/2018-05-07-Lannett-Announces-Fiscal-2018-Third-Quarter-Financial-Results --Adjusted EPS Higher Than Expected; Outlook for Fiscal 2018 Net Sales and Adjusted Profitability Affirmed-- Mon, 07 May 2018 16:15:00 -0400 http://lannett.investorroom.com/2018-05-07-Lannett-Announces-Fiscal-2018-Third-Quarter-Financial-Results Lannett Acquires Portfolio Of Generic Products From Endo International http://lannett.investorroom.com/2018-05-07-Lannett-Acquires-Portfolio-Of-Generic-Products-From-Endo-International --Transaction Includes 23 Approved and 1 Pending Drug Product Applications, Primarily Oral Solutions-- Mon, 07 May 2018 06:53:00 -0400 http://lannett.investorroom.com/2018-05-07-Lannett-Acquires-Portfolio-Of-Generic-Products-From-Endo-International